According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- From Hypertension to Heart Failure?
When and how to intervene
- Switzerland's First PTH Replacement Therapy
Palopegteriparatide for Chronic Hypoparathyroidism
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Quitting smoking reduces cardiovascular risks
Offer professional support
- CKD and High Blood Pressure
Keeping an Eye on Bidirectional Interactions
- Atherosclerotic Coronary Plaques in High-Risk Patients
Who benefits from preventive PCI?
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Colorectal Cancer